NCT02479178终止2 期
A Phase 2 Study to Determine the Efficacy and Safety of BIND-014 (Docetaxel Nanoparticles for Injectable Suspension) in Patients With Urothelial Carcinoma, Cholangiocarcinoma, Cervical Cancer and Squamous Cell Carcinoma of the Head and Neck
适应症
相关药物
试验速览
- 阶段
- 2 期
- 状态
- 终止
- 入组人数
- 73
- 试验地点
- 45
- 主要终点
- To determine the objective response rate (ORR) in patients with advanced urothelial carcinoma (transitional cell carcinoma), cervical cancer, cholangiocarcinoma or carcinomas of the biliary tree and squamous cell carcinoma of the head and neck.
研究概览
简要总结
BIND-014 (docetaxel nanoparticles for injectable suspension) is being studied in patients with advanced urothelial carcinoma, cervical cancer, cholangiocarcinoma or carcinomas of the biliary tree and squamous cell carcinoma of the head and neck.
Ferumoxytol imaging will also be investigated at US sites as an exploratory endpoint.
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Diagnosis of advanced urothelial carcinoma, cervical cancer, cholangiocarcinoma or carcinomas of the biliary tree or squamous cell carcinoma of the head and neck.
- •Progressive disease after ≥ 1 prior chemotherapy regimen.
- •Patients with brain metastases are eligible if asymptomatic and neurologically stable for at least 4 weeks and are not taking any medications contraindicated
- •Chemotherapy must have been completed at least 4 weeks prior to initiation of study medication
- •ECOG performance status 0-1
- •Tumors must have measurable disease as per RECIST (version 1.1);
- •Female or male, 18 years of age or older
- •Adequate organ function
- •Life expectancy of > 3 months
排除标准
- •Current treatment on another therapeutic clinical trial
- •Prior treatment with docetaxel within 6 months of enrollment
- •Stage II, III or IV cardiac failure
- •Carcinomatous meningitis
- •Ongoing cardiac dysrhythmias
- •Peripheral neuropathy
- •Serious concomitant conditions
- •Pregnant or breast feeding
- •Known sensitivity to ferumoxytol
- •Hypersensitivity to polysorbate 80
结局指标
主要结局
To determine the objective response rate (ORR) in patients with advanced urothelial carcinoma (transitional cell carcinoma), cervical cancer, cholangiocarcinoma or carcinomas of the biliary tree and squamous cell carcinoma of the head and neck.
时间窗: 18 weeks
Patients will be followed for ORR for an expected average of 18 weeks
次要结局
- Progression Free Survival(Change in tumor size will be assessed using RECIST measurements. RECIST assessments will be carried out at baseline, week 6, week 12 and every 6 weeks thereafter relative to first dose of study drug, an expected average of 18 weeks.)
- Overall Survival(Participants will be followed for survival, an expected average 24 weeks after treatment discontinuation)
- Best Response(Change in tumor size will be assessed using RECIST measurements. RECIST assessments to be carried out at baseline, week 6, week 12 and every 6 weeks thereafter relative to first dose of study drug, an expected average 18 weeks)
- Duration of Response(Change in tumor size will be assessed using RECIST measurements. RECIST assessments to be carried out at baseline, week 6, week 12 and every 6 weeks thereafter relative to first dose of study drug, an expected average 18 weeks)
- Time to Response(change in tumor size will be assessed using RECIST measurements. RECIST assessments to be carried out at baseline, week 6, week 12 relative to first dose of study drug)
- Disease Control Rate(Change in tumor size will be assessed using RECIST measurements. RECIST assessments to be carried out at baseline, week 6, week 12 and every 6 weeks thereafter relative to first dose of study drug, an expected average 18 weeks)
- Safety and Tolerability, as measured by number of participants with adverse events(Measured from first dose of study drug until 30 days after study discontinuation)
研究者
研究点 (45)
Loading locations...
相似试验
已完成
2 期
A Study of BIND-014 (Docetaxel Nanoparticles for Injectable Suspension) as Second-line Therapy for Patients With KRAS Positive or Squamous Cell Non-Small Cell Lung CancerKRAS Positive Patients With Non-small Cell Lung CancerSquamous Cell Non-small Cell Lung CancerNCT02283320BIND Therapeutics69
已完成
2 期
A Phase 2 Study to Determine the Safety and Efficacy of BIND-014 (Docetaxel Nanoparticles for Injectable Suspension) as Second-line Therapy to Patients With Non-Small Cell Lung CancerNon-small Cell Lung CancerNCT01792479BIND Therapeutics64
撤回
2 期
Neoadjuvant Docetaxel on Newly Diagnosed Intermediate and High Grade Cancer of the ProstateAdenocarcinoma of the ProstateStage I Prostate CancerStage II Prostate CancerProstate CancerNCT00598858John P. Fruehauf
已完成
2 期
A Phase 2 Study to Determine the Safety and Efficacy of BIND-014 (Docetaxel Nanoparticles for Injectable Suspension), Administered to Patients With Metastatic Castration-Resistant Prostate CancerCRPCProstate CancerNCT01812746BIND Therapeutics42
已完成
2 期
A Double-blind Study Evaluating IPI-504 and Docetaxel in Patients With Non-Small Cell Lung CancerNon Small Cell Lung CancerNCT01362400Infinity Pharmaceuticals, Inc.226